Evidence map›Paper›PMID 28919249›Full record

Observational studyPractical radiation oncology

Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study.

Peter Paximadis, Matthew Schipper, Martha Matuszak, Mary Feng, Shruti Jolly, Thomas Boike, Inga Grills, Larry Kestin, Benjamin Movsas, Kent Griffith and 8 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Modeling Time-Dependent Recovery to Improve Esophagitis Prediction in Thoracic Reirradiation.International journal of radiation oncology, biology, physics · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Peter PaximadisKarmanos Cancer Center, Detroit, Michigan. Electronic address: paximadp@karmanos.org.
Matthew SchipperUniversity of Michigan, Ann Arbor, Michigan.
Martha MatuszakUniversity of Michigan, Ann Arbor, Michigan.
Mary FengUniversity of Michigan, Ann Arbor, Michigan.
Shruti JollyUniversity of Michigan, Ann Arbor, Michigan.
Thomas BoikeMcLaren Northern Michigan, Petoskey, Michigan.
Inga GrillsWilliam Beaumont Hospital, Royal Oak, Michigan.
Larry Kestin21st Century Oncology, Farmington Hills, Michigan.
Benjamin MovsasHenry Ford Hospital, Detroit, Michigan.
Kent GriffithUniversity of Michigan, Ann Arbor, Michigan.
Gregory GustafsonWilliam Beaumont Hospital, Royal Oak, Michigan.
Jean MoranUniversity of Michigan, Ann Arbor, Michigan.
Teamour Nurushev21st Century Oncology, Farmington Hills, Michigan.
Jeffrey RadawskiWest Michigan Cancer Center, Rockford, Michigan.
Lori PierceUniversity of Michigan, Ann Arbor, Michigan.
James HaymanUniversity of Michigan, Ann Arbor, Michigan.
on behalf of
Michigan Radiation Oncology Quality Consortium
University of Michigan–Ann Arbor · US21st Century Oncology (United States) · USBeaumont Hospital, Royal Oak · USHenry Ford Hospital · USMcLaren Northern Michigan · USThe Barbara Ann Karmanos Cancer Institute · USWest Michigan Cancer Center · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
NCI NIH HHS P30 CA022453
6 · The paper itself

Abstract

purposeThe purpose of this study is to identify dosimetric variables that best predict for acute esophagitis in patients treated for locally advanced non-small cell lung cancer in a prospectively accrued statewide consortium. METHODS AND MATERIALS: Patients receiving definitive radiation therapy for stage II-III non-small cell lung cancer within the Michigan Radiation Oncology Quality Consortium were included in the analysis. Dose-volume histogram data were analyzed to determine absolute volumes (cc) receiving doses from 10 to 60 Gy (V10, V20, V30, V40, V50, and V60), as well as maximum dose to 2 cc (D2cc), mean dose (MD), and generalized equivalent uniform dose (gEUD). Logistic regression models were used to characterize the risk of toxicity as a function of dose and other covariates. The ability of each variable to predict esophagitis, individually or in a multivariate model, was quantified by receiver operating characteristic analysis.

resultsThere were 533 patients who met study criteria and were included; 437 (81.9%) developed any grade of esophagitis. Significant variables on univariate analysis for grade ≥2 esophagitis were concurrent chemotherapy, V20, V30, V40, V50, V60, MD, D2cc, and gEUD. For grade ≥3 esophagitis, the predictive variables were: V30, V40, V50, V60, MD, D2cc, and gEUD. In multivariable modeling, gEUD was the most significant predictor of both grade ≥2 and grade ≥3 esophagitis. When gEUD was excluded from the model, D2cc was selected as the most predictive variable for grade ≥3 esophagitis. For an estimated risk of grade ≥3 esophagitis of 5%, the threshold values for gEUD and D2cc were 59.3 Gy and 68 Gy, respectively.

conclusionsIn this study, we report the novel finding that gEUD and D2cc, rather than MD, were the most predictive dose metrics for severe esophagitis. To limit the estimated risk of grade ≥3 esophagitis to <5%, thresholds of 59.3 Gy and 68 Gy were identified for gEUD and D2cc, respectively.

Indexed as

Acute DiseaseAgedEsophagitisFemaleHumansLung NeoplasmsMaleProspective StudiesRadiotherapy Planning, Computer-Assisted

Identifiers

PMID28919249
PMCPMC6818411
OpenAlexW2736472997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.